))
S2E04: Alex Harding - Biotech Investing, Entrepreneurship and Drug Pricing
Manage episode 313065883 series 3257692
Contenido proporcionado por Sharif Vakili. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Sharif Vakili o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Is it possible for market competition to lower drug prices in pharma, or are we resigned to ever-increasing prices with each new biotech innovation? Dr. Alex Harding, biotech venture capitalist at Atlas Ventures, VP of Business Development and Corporate Strategy at Remix Therapeutics and MGH internal medicine physician, joins for a multifaceted conversation around drug pricing, being a practicing physician in biotech VC, and life sciences entrepreneurship. A contributor to the biotech newsletter the Timmerman Report, Alex discusses his recent report on the disruptive drug discovery startup, EQRx, that is contending to radically lower drug prices. Join for a thought-provoking conversation around the consequences of EQRx’s business model and the challenges with market-based drug pricing reform in the United States.
This episode marks the end of the summer interseason. The Doctor is Out will be back in a few months after a short break.
36 episodios
Compartir
